Effects of different doses of dexmedetomidine combined with remifentanil for gastrectomy polypectomy and/or esophageal polypectomy, a prospective, randomized, single-blinded controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032401

Enrollment

Unknown

Registered

2020-04-27

Start date

2020-05-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the anesthesia method of gastrectomy polypectomy and/or esophageal polypectomy

Interventions

low-dose dexmedetomidine group:the low dose dexmedetomidine + constant dose remifentanil were continuously pumped

medium-dose dexmedetomidine group:the middle dose dexmedetomidine + constant dose remifentanil were continuously pumped

high-dose dexmedetomidine group:the high dose dexmedetomidine + constant dose remifentanil were continuously pumped

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 150 patients with multiple esophageal/gastric polyps were selected for selective operation. There was no limit to gender. The age was 30-70 years old. ASA grade I-II, body mass index (BMI) 20-29kg/?. There is no basic disease in the cardiopulmonary system. Patients who are willing to sign informed consent must be able to understand and willing to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with endoscopy contraindications; 3. Patients with dexmedetomidine hypersensitivity; 4. Patients with severe cardiopulmonary function, liver and kidney dysfunction; 5. Patients with severe snoring and obesity (BMI > 30kg/?); 6. Patients with severe heart rate slow (heart rate < 60 times/min); 7. Patients with acute upper gastrointestinal bleeding; 8. Hypertension, diabetes, mental disorder and mental disorder.

Design outcomes

Primary

Measure	Time frame
Basic information of patients;Effective time of drug;Perioperative vital signs;Respiratory rate and intraoperative awareness;Blood concentration;bispectral index,BIS;Observer Assessment of Sedation (OAAS);Observation of intraoperative indexes;Recovery time (recovery room stay time);Consciousness index;Intraoperative drug use;Observation of various indexes of patients during operation;Collection of basic parameters of the model;	—

Measure

Time frame

Basic information of patients;Effective time of drug;Perioperative vital signs;Respiratory rate and intraoperative awareness;Blood concentration;bispectral index,BIS;Observer Assessment of Sedation (OAAS);Observation of intraoperative indexes;Recovery time (recovery room stay time);Consciousness index;Intraoperative drug use;Observation of various indexes of patients during operation;Collection of basic parameters of the model;

—

Countries

China

Contacts

Public ContactGuofa Shan

Funing People's Hospital of Jiangsu Province

278189607@qq.com+86 13605101785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026